NO771766L - Fremgangsm}te til fremstilling av et nytt farmas¦ytisk preparat - Google Patents

Fremgangsm}te til fremstilling av et nytt farmas¦ytisk preparat

Info

Publication number: NO771766L
Authority: NO; Norway
Prior art keywords: active ingredient; preparation; pharmaceutically acceptable; propyl; acceptable salt
Prior art date: 1976-05-21

Application number

NO771766A

Other languages

English (en)

Norwegian (no)

Inventor

Thomas Samuel Campbell

Raymond William Keogh

Brian Carman Meakin

Original Assignee

Fisons Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-05-21

Filing date

1977-05-20

Publication date

1977-11-22

1977-05-20 Application filed by Fisons Ltd filed Critical Fisons Ltd

1977-11-22 Publication of NO771766L publication Critical patent/NO771766L/no

Links

238000000034 method Methods 0.000 title claims description 48
239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
239000004480 active ingredient Substances 0.000 claims description 46
238000002360 preparation method Methods 0.000 claims description 43
150000001875 compounds Chemical class 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 17
239000002904 solvent Substances 0.000 claims description 17
239000002674 ointment Substances 0.000 claims description 13
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 11
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
210000003491 skin Anatomy 0.000 claims description 10
239000012188 paraffin wax Substances 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 8
150000002148 esters Chemical class 0.000 claims description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
239000006071 cream Substances 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 7
239000000463 material Substances 0.000 claims description 6
239000000843 powder Substances 0.000 claims description 6
239000002562 thickening agent Substances 0.000 claims description 6
150000002191 fatty alcohols Chemical class 0.000 claims description 5
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
239000003921 oil Substances 0.000 claims description 5
239000002245 particle Substances 0.000 claims description 5
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
150000001298 alcohols Chemical class 0.000 claims description 4
229940086737 allyl sucrose Drugs 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
230000003111 delayed effect Effects 0.000 claims description 4
239000003995 emulsifying agent Substances 0.000 claims description 4
239000006210 lotion Substances 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
229920000642 polymer Polymers 0.000 claims description 4
239000003755 preservative agent Substances 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
239000000344 soap Substances 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
229910052791 calcium Inorganic materials 0.000 claims description 3
239000011575 calcium Substances 0.000 claims description 3
230000001413 cellular effect Effects 0.000 claims description 3
229940057995 liquid paraffin Drugs 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
150000007530 organic bases Chemical class 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
210000002268 wool Anatomy 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
125000000129 anionic group Chemical group 0.000 claims description 2
235000013871 bee wax Nutrition 0.000 claims description 2
239000012166 beeswax Substances 0.000 claims description 2
239000000440 bentonite Substances 0.000 claims description 2
229910000278 bentonite Inorganic materials 0.000 claims description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
229960002903 benzyl benzoate Drugs 0.000 claims description 2
125000002091 cationic group Chemical group 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
239000006185 dispersion Substances 0.000 claims description 2
238000004090 dissolution Methods 0.000 claims description 2
239000008387 emulsifying waxe Substances 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
210000003630 histaminocyte Anatomy 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
235000019388 lanolin Nutrition 0.000 claims description 2
229940040145 liniment Drugs 0.000 claims description 2
239000000865 liniment Substances 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
229940068965 polysorbates Drugs 0.000 claims description 2
229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
239000012047 saturated solution Substances 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
150000003536 tetrazoles Chemical class 0.000 claims description 2
229960001760 dimethyl sulfoxide Drugs 0.000 claims 1
239000007764 o/w emulsion Substances 0.000 claims 1
239000003206 sterilizing agent Substances 0.000 claims 1
239000007762 w/o emulsion Substances 0.000 claims 1
239000002585 base Substances 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
239000000499 gel Substances 0.000 description 8
-1 5-(1H)tetrazolyl Chemical group 0.000 description 7
208000010247 contact dermatitis Diseases 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
239000002253 acid Substances 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
159000000000 sodium salts Chemical class 0.000 description 5
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
208000010668 atopic eczema Diseases 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
241000700198 Cavia Species 0.000 description 3
206010012438 Dermatitis atopic Diseases 0.000 description 3
241000283086 Equidae Species 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
241000721454 Pemphigus Species 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
201000008937 atopic dermatitis Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
208000002399 aphthous stomatitis Diseases 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
229910052759 nickel Inorganic materials 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
206010062269 Adrenalitis Diseases 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
206010006500 Brucellosis Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
208000019872 Drug Eruptions Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
240000006711 Pistacia vera Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046752 Urticaria Pigmentosa Diseases 0.000 description 1
125000005041 acyloxyalkyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
239000013566 allergen Substances 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical class [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
229940043276 diisopropanolamine Drugs 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000008308 lipophilic cream Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
208000030179 maculopapular cutaneous mastocytosis Diseases 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
OKRFIJBHGCRXQH-UHFFFAOYSA-N octadecanoic acid;propan-2-yl hexadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(=O)OC(C)C OKRFIJBHGCRXQH-UHFFFAOYSA-N 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
208000009954 pyoderma gangrenosum Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

NO771766A 1976-05-21 1977-05-20 Fremgangsm}te til fremstilling av et nytt farmas¦ytisk preparat NO771766L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB20986/76A GB1560489A (en)	1976-05-21	1976-05-21	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
NO771766L true NO771766L (no)	1977-11-22

Family

ID=10155228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO771766A NO771766L (no)	1976-05-21	1977-05-20	Fremgangsm}te til fremstilling av et nytt farmas¦ytisk preparat

Country Status (18)

Country	Link
US (2)	US4160844A (fr)
JP (1)	JPS5315428A (fr)
AU (1)	AU508191B2 (fr)
BE (1)	BE854691A (fr)
CA (1)	CA1085298A (fr)
DE (1)	DE2722916A1 (fr)
DK (1)	DK223377A (fr)
FI (1)	FI771582A7 (fr)
FR (1)	FR2361387A1 (fr)
GB (1)	GB1560489A (fr)
IE (1)	IE45200B1 (fr)
IL (1)	IL52103A (fr)
LU (1)	LU77365A1 (fr)
NL (1)	NL7705561A (fr)
NO (1)	NO771766L (fr)
NZ (1)	NZ184140A (fr)
SE (1)	SE7705851L (fr)
ZA (1)	ZA772990B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1560489A (en) *	1976-05-21	1980-02-06	Fisons Ltd	Pharmaceutical compositions
EP0008167A1 (fr) *	1978-08-15	1980-02-20	FISONS plc	Procédé amélioré pour la fabrication de l'acide tétrahydro-6,7,8,9-hydroxy-5 oxo-4 propyl-10 4H naphto(2,3-b)pyranne-carboxylique-2
US4935435A (en) *	1988-04-11	1990-06-19	May & Baker Limited	Use of tetrazole derivatives
SK282721B6 (sk) *	1994-05-27	2002-11-06	Smithkline Beecham S.P.A.	Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
US6750160B1 (en)	1996-12-09	2004-06-15	Kao Corporation	Detergent-impregnated article
DE60129473T2 (de) *	2001-03-30	2008-04-03	Color Access, Inc.	Eingekapselte farbstoffe in kosmetische zubereitungen
US7115287B2 (en) *	2005-03-03	2006-10-03	F.L.M., L.L.C.	Topical medicament and method of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE817137C (de) *	1948-10-02	1951-10-15	Neuerburg Obsterei K G	Walze zum Kristallisieren von Fluessigkeiten
US3864493A (en) *	1967-08-17	1975-02-04	Fisons Ltd Felixstowe	Compositions and methods for the prevention of asthmatic symptoms
US3873714A (en) *	1971-07-14	1975-03-25	Syntex Inc	Xanthone carboxylic acids and derivatives
US4133889A (en) *	1971-07-29	1979-01-09	Fisons, Ltd.	2(5-Tetrazolyl)chromones
GB1389227A (en) *	1971-09-16	1975-04-03	Fisons Ltd	Chromone-2-carboxylic acid derivatives methods for their preparation and compositions containing them
JPS5118955B2 (fr) *	1972-04-12	1976-06-14
GB1517153A (en)	1974-11-30	1978-07-12	Fisons Ltd	Naphthopyran-and benzodipyran-2-carboxylic acids and derivatives thereof
GB1560489A (en) *	1976-05-21	1980-02-06	Fisons Ltd	Pharmaceutical compositions

1976
- 1976-05-21 GB GB20986/76A patent/GB1560489A/en not_active Expired
1977
- 1977-05-05 US US05/794,030 patent/US4160844A/en not_active Expired - Lifetime
- 1977-05-09 CA CA278,142A patent/CA1085298A/fr not_active Expired
- 1977-05-16 BE BE177620A patent/BE854691A/fr unknown
- 1977-05-16 IL IL52103A patent/IL52103A/xx unknown
- 1977-05-16 FR FR7714859A patent/FR2361387A1/fr active Granted
- 1977-05-17 AU AU25196/77A patent/AU508191B2/en not_active Expired
- 1977-05-17 SE SE7705851A patent/SE7705851L/xx unknown
- 1977-05-18 ZA ZA00772990A patent/ZA772990B/xx unknown
- 1977-05-18 LU LU77365A patent/LU77365A1/xx unknown
- 1977-05-18 FI FI771582A patent/FI771582A7/fi not_active Application Discontinuation
- 1977-05-18 NZ NZ184140A patent/NZ184140A/xx unknown
- 1977-05-19 JP JP5712877A patent/JPS5315428A/ja active Pending
- 1977-05-20 IE IE1039/77A patent/IE45200B1/en unknown
- 1977-05-20 DK DK223377A patent/DK223377A/da not_active Application Discontinuation
- 1977-05-20 NO NO771766A patent/NO771766L/no unknown
- 1977-05-20 NL NL7705561A patent/NL7705561A/xx not_active Application Discontinuation
- 1977-05-20 DE DE19772722916 patent/DE2722916A1/de not_active Withdrawn
1979
- 1979-03-05 US US06/017,422 patent/US4269853A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
FR2361387A1 (fr)	1978-03-10
IL52103A0 (en)	1977-07-31
US4160844A (en)	1979-07-10
CA1085298A (fr)	1980-09-09
ZA772990B (en)	1978-04-26
FI771582A7 (fr)	1977-11-22
NZ184140A (en)	1978-06-20
AU2519677A (en)	1978-11-23
IE45200B1 (en)	1982-07-14
GB1560489A (en)	1980-02-06
IE45200L (en)	1977-11-21
DK223377A (da)	1977-11-22
JPS5315428A (en)	1978-02-13
LU77365A1 (fr)	1977-12-13
FR2361387B1 (fr)	1980-05-09
AU508191B2 (en)	1980-03-13
NL7705561A (nl)	1977-11-23
IL52103A (en)	1981-09-13
US4269853A (en)	1981-05-26
BE854691A (fr)	1977-11-16
SE7705851L (sv)	1977-11-22
DE2722916A1 (de)	1977-12-01

Publication	Publication Date	Title
DE69600242T2 (de)	1998-08-06	Verwendung von Extrakten aus filamentösen, nicht photosynthetischen Bakterien sowie ihre Zusammensetzungen
DE69601765T2 (de)	1999-07-08	Extrakt von Iridaceen und Zusammensetzungen, die ihn enthalten
DE69520032T2 (de)	2001-05-23	Topische Zusammensetzung enthaltend ein Antagonist der Substanz P
EP0098743B1 (fr)	1988-09-28	Dérivés de phényl-alpha-acyloxyacétamides et leur utilisation thérapeutique
DE60032795T2 (de)	2007-11-08	Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
EP3677265B1 (fr)	2025-10-01	Composition pour prévenir ou traiter les troubles du sommeil
DE69522188T2 (de)	2001-11-29	Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung
DE69504949T2 (de)	1999-02-18	Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs
JP2010184903A (ja)	2010-08-26	外用医薬組成物
NO771766L (no)	1977-11-22	Fremgangsm}te til fremstilling av et nytt farmas¦ytisk preparat
DE2759171A1 (de)	1979-07-12	Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
WO2000050019A2 (fr)	2000-08-31	UTILISATION D'ACIDES R-ARYL-PROPIONIQUES POUR LA PRODUCTION DE MEDICAMENTS, POUR LE TRAITEMENT DE MALADIES TOUCHANT L'HOMME ET L'ANIMAL ET SUR LESQUELLES L'INHIBITION DE L'ACTIVATION DU FACTEUR DE TRANSCRIPTION NF-λB PEUT EXERCER UNE INFLUENCE D'UN POINT DE VUE THERAPEUTIQUE
CA2165519C (fr)	2002-07-16	Utilisation d'un antagoniste de substance p pour le traitement des prurits, des algies oculaires et/ou palpebrales et des dysesthesies oculaires ou palpebrales
EP0294914A2 (fr)	1988-12-14	Nédocromil pour le traitement des maladies dermatologiques
JP5438239B1 (ja)	2014-03-12	シコニン誘導体を有するペリオスチンの発現抑制剤
US20250319094A1 (en)	2025-10-16	Composition for preventing or treating atopic dermatitis
DE2634908C2 (fr)	1988-12-29
KR101981482B1 (ko)	2019-05-23	에틸 페룰레이트를 유효성분으로 포함하는 알러지 완화용 조성물
RU2426540C1 (ru)	2011-08-20	Противовоспалительное и противоаллергическое лекарственное средство и фармацевтическая композиция на его основе
CN114053259B (zh)	2025-07-22	包含麝香草酚三甲氧基肉桂酸酯的皮肤瘙痒或刺激缓解用组合物
KR102689151B1 (ko)	2024-07-29	Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2013085347A1 (fr)	2013-06-13	Nouveaux dérivés de la phytosphingosine et composition cosmétique les comprenant destinés à la prévention et à l'évolution favorable de maladies inflammatoires de la peau et de l'hyperkératose
US3471615A (en)	1969-10-07	Griseofulvin-perezone composition
CN120603601A (zh)	2025-09-05	用于治疗马拉色菌酵母引起的病状的鳄梨不皂化物
JP2000086529A (ja)	2000-03-28	Ｉｌ−４産生抑制剤